Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences

AIMS: To characterize gastrointestinal adverse events (AEs) with different glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). METHODS: Two retrospective intention‐to‐treat analyses of 6‐month patient‐level data were conducted. Data from three studies comparing exenatide once weekly (n = 617) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Horowitz, Michael, Aroda, Vanita R., Han, Jenny, Hardy, Elise, Rayner, Chris K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412849/
https://www.ncbi.nlm.nih.gov/pubmed/28058769
http://dx.doi.org/10.1111/dom.12872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412849/
https://www.ncbi.nlm.nih.gov/pubmed/28058769
http://dx.doi.org/10.1111/dom.12872

Ejemplares similares